Research programme: Liposomal cytotoxic compounds - GP Pharm

Drug Profile

Research programme: Liposomal cytotoxic compounds - GP Pharm

Latest Information Update: 22 Jan 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator GP Pharm
  • Class Alkaloids; Anthracyclines; Antineoplastics; Camptothecins; Deoxyribonucleosides; Doxorubicins; Pyrimidine nucleosides; Small molecules; Taxanes
  • Mechanism of Action DNA intercalators; DNA synthesis inhibitors; Mitosis inhibitors; Tubulin modulators; Tubulin polymerisation promoters; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 22 Jan 2016 Preclinical trials in Cancer in Spain (parenteral) before January 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top